Improving treatment outcome in paediatric acute lymphoblastic leukaemia by minimal residual disease detection and pharmacokinetics

该项目的主要目标是通过更多地使用分子诊断学来测量微小残留病，并通过药代动力学测试来确定一种关键化疗药物(聚乙二醇-L-天冬酰胺酶)对参加国际临床试验的澳大利亚患者的有效性，从而大幅改善儿童白血病患者的治疗。该试验旨在减少复发和长期副作用的发生率。

The main objective of this project is to make substantial improvements in the treatment of patients with childhood leukaemia by greater use of molecular diagnostics to measure minimal residual disease (MRD) and pharmacokinetic testing to determine the effectiveness of a key chemotherapy drug (PEG-L-Asparaginase) in Australian patients enrolled on an international clinical trial which has been designed to reduce the incidence of both relapses and long term side-effects.